CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 264 enrolled
Drug / intervention
sulfonylurea +2 moredrug
Likely dose
liraglutide 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00395746
NCT00395746Phase 3Completed
CompareCT.gov

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Nov 3, 2006·Updated Mar 8, 2017

In Brief

A Phase 3 clinical trial evaluating sulfonylurea and liraglutide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 264 participants across 1 site.

Detailed Summary

This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52 weeks in subjects with type 2 diabetes. Liraglutide will be compared to placebo, in combination with SU. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2006
Enrollment StartOct 1, 2006
Primary CompletionOct 1, 2007
Study CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.7 years ago

Interventions

sulfonylureadrug

SU agent

liraglutidedrug

Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.

liraglutidedrug

Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.